{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:54Z","timestamp":1792785054046,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tehran University of Medical Sciences","award":["1404-14-104-95346"],"award-info":[{"award-number":["1404-14-104-95346"]}],"id":[{"id":"https:\/\/ror.org\/01c4pz451","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In an attempt to identify novel \u03b1\u2011glucosidase inhibitors, a new series of substituted imidazo[1,2\u2011a]pyridine derivatives (10a\u201310ab) was designed, synthesized, and evaluated for their inhibitory activities. All compounds exhibited potent inhibition, with IC\n                    <jats:sub>50<\/jats:sub>\n                    values ranging from 12.01 to 93.01 \u00b5M, significantly better than acarbose IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u2009750.02 \u00b5M). SAR analysis highlighted the critical role of para\u2011substitution on the benzamide ring, especially methoxy groups. The most potent compound, 10s (IC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009=\u200912.01 \u00b5M), acted as a competitive inhibitor (K\n                    <jats:sub>i<\/jats:sub>\n                    = 21 \u00b5M) with no\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \u2011amylase inhibition, indicating high selectivity. It was non\u2011cytotoxic up to 100 \u00b5M. Circular dichroism, fluorescence spectroscopy, and thermodynamic analysis revealed strong ligand\u2013enzyme interactions mainly driven by hydrophobic forces. Molecular docking and 200 ns MD simulations, including MM\u2011GBSA calculations, supported stable binding of\n                    <jats:bold>10s<\/jats:bold>\n                    within the active site. Collectively, these results introduce imidazo[1,2-\n                    <jats:italic>a<\/jats:italic>\n                    ]pyridine derivative 10s as a promising lead compound for the development of novel \u03b1-glucosidase inhibitors in further studies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-61309-9","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:33:59Z","timestamp":1783784039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel imidazo[1,2-a]pyridine-based \u03b1-glucosidase inhibitors: synthesis, biological evaluations, and computational studies"],"prefix":"10.1038","volume":"16","author":[{"given":"Maryam","family":"Norouzbahari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Emamgholipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Peytam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toktam","family":"Saadattalab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Bayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin Ozan","family":"Gulcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Mojtabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Bijanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loghman","family":"Firoozpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Foroumadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"61309_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"61309_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong, K. L. et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6 (2023).","journal-title":"Lancet"},{"key":"61309_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu, X. et al. Type 2 diabetes mellitus in adults: Pathogenesis, prevention and therapy. Signal Transduct. Target. Ther. 9, 262. https:\/\/doi.org\/10.1038\/s41392-024-01951-9 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"61309_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","volume":"47","author":"ED Parker","year":"2024","unstructured":"Parker, E. D. et al. Economic costs of diabetes in the US in 2022. Diabetes Care. 47, 26\u201343. https:\/\/doi.org\/10.2337\/dci23-0085 (2024).","journal-title":"Diabetes Care"},{"key":"61309_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2147\/vhrm.s3119","volume":"4","author":"FA Van de Laar","year":"2008","unstructured":"Van de Laar, F. A. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc. Health Risk Manag. 4, 1189\u20131195. https:\/\/doi.org\/10.2147\/vhrm.s3119 (2008).","journal-title":"Vasc. Health Risk Manag."},{"key":"61309_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108762","volume":"163","author":"R Jha","year":"2025","unstructured":"Jha, R., Goyal, K., Mehan, S. & Singh, G. Dual \u03b1-amylase and \u03b1-glucosidase inhibitors: Recent progress from natural and synthetic resources. Bioorg. Chem. 108762. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108762 (2025).","journal-title":"Bioorg. Chem."},{"key":"61309_CR7","first-page":"78","volume":"18","author":"G Arungarinathan","year":"2011","unstructured":"Arungarinathan, G., McKay, G. A. & Fisher, M. Drugs for diabetes: part 4 acarbose. Br. J. Cardiol. 18, 78\u201381 (2011).","journal-title":"Br. J. Cardiol."},{"key":"61309_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejmech.2019.04.025","volume":"176","author":"M Dhameja","year":"2019","unstructured":"Dhameja, M. & Gupta, P. Synthetic heterocyclic candidates as promising \u03b1-glucosidase inhibitors: An overview. Eur. J. Med. Chem. 176, 343\u2013377. https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.025 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"61309_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135115","volume":"1281","author":"A Singh","year":"2023","unstructured":"Singh, A. et al. Recent developments in synthetic \u03b1-glucosidase inhibitors: A comprehensive review with structural and molecular insight. J. Mol. Struct. 1281, 135115. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135115 (2023).","journal-title":"J. Mol. Struct."},{"key":"61309_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115119","volume":"249","author":"A Mushtaq","year":"2023","unstructured":"Mushtaq, A., Azam, U., Mehreen, S. & Naseer, M. M. Synthetic \u03b1-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges. Eur. J. Med. Chem. 249, 115119. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115119 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"61309_CR11","doi-asserted-by":"publisher","unstructured":"Keshtmand, M. & Sadeghi, M. Identification of \u0391-Glucosidase Inhibitors from Alkaloids for Possible Treatment of Diabetes Mellitus Disease: In Silico and in Vitro Approaches. Available at SSRN 5393924. https:\/\/doi.org\/10.2139\/ssrn.5393924","DOI":"10.2139\/ssrn.5393924"},{"key":"61309_CR12","doi-asserted-by":"publisher","first-page":"22951","DOI":"10.1039\/d2ra02697j","volume":"12","author":"U Farwa","year":"2022","unstructured":"Farwa, U. & Raza, M. A. Heterocyclic compounds as a magic bullet for diabetes mellitus: a review. RSC Adv. 12, 22951\u201322973. https:\/\/doi.org\/10.1039\/d2ra02697j (2022).","journal-title":"RSC Adv."},{"key":"61309_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37467","author":"G Pan","year":"2024","unstructured":"Pan, G. et al. A review on the in vitro and in vivo screening of \u03b1-glucosidase inhibitors. Heliyon https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37467 (2024).","journal-title":"Heliyon"},{"key":"61309_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202401109","volume":"21","author":"A Singh","year":"2024","unstructured":"Singh, A. et al. Recent developments in 1, 2, 3-triazole based \u03b1\u2010glucosidase inhibitors: Design strategies, structure\u2010activity relationship and mechanistic insights. Chem. Biodivers. 21, e202401109. https:\/\/doi.org\/10.1002\/cbdv.202401109 (2024).","journal-title":"Chem. Biodivers."},{"key":"61309_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/0115734064264591231031065639","volume":"20","author":"P Patel","year":"2024","unstructured":"Patel, P. et al. A review on the development of novel heterocycles as \u03b1-glucosidase inhibitors for the treatment of type-2 diabetes mellitus. Med. Chem. 20, 503\u2013536. https:\/\/doi.org\/10.2174\/0115734064264591231031065639 (2024).","journal-title":"Med. Chem."},{"key":"61309_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29112668","volume":"29","author":"G Volpi","year":"2024","unstructured":"Volpi, G., Laurenti, E. & Rabezzana, R. Imidazopyridine family: Versatile and promising heterocyclic skeletons for different applications. Molecules 29, 2668. https:\/\/doi.org\/10.3390\/molecules29112668 (2024).","journal-title":"Molecules"},{"key":"61309_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111569","volume":"181","author":"D Vanda","year":"2019","unstructured":"Vanda, D., Zajdel, P. & Soural, M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. Eur. J. Med. Chem. 181, 111569. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111569 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"61309_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106831","volume":"140","author":"F Peytam","year":"2023","unstructured":"Peytam, F. et al. Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review. Bioorg. Chem. 140, 106831. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106831 (2023).","journal-title":"Bioorg. Chem."},{"key":"61309_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121680","volume":"11","author":"BKR Sanapalli","year":"2022","unstructured":"Sanapalli, B. K. R. et al. Synthetic imidazopyridine-based derivatives as potential inhibitors against multi-drug resistant bacterial infections: A review. Antibiotics 11, 1680. https:\/\/doi.org\/10.3390\/antibiotics11121680 (2022).","journal-title":"Antibiotics"},{"key":"61309_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/1568026616666160530153233","volume":"17","author":"A Deep","year":"2017","unstructured":"Deep, A. et al. Imidazo [1, 2-a] pyridine scaffold as prospective therapeutic agents. Curr. Top. Med. Chem. 17, 238\u2013250. https:\/\/doi.org\/10.2174\/1568026616666160530153233 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"61309_CR21","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1080\/07391102.2021.1873861","volume":"40","author":"S Mahernia","year":"2022","unstructured":"Mahernia, S. et al. The possible effect of microRNA-155 (miR-155) and BACE1 inhibitors in the memory of patients with down syndrome and Alzheimer\u2019s disease: Design, synthesis, virtual screening, molecular modeling and biological evaluations. J. Biomol. Struct. Dyn. 40, 5803\u20135814. https:\/\/doi.org\/10.1080\/07391102.2021.1873861 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"61309_CR22","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s11030-020-10137-8","volume":"25","author":"M Saeedi","year":"2021","unstructured":"Saeedi, M. et al. Synthesis of 4-alkylaminoimidazo [1, 2-a] pyridines linked to carbamate moiety as potent \u03b1-glucosidase inhibitors. Mol. Diversity. 25, 2399\u20132409. https:\/\/doi.org\/10.1007\/s11030-020-10137-8 (2021).","journal-title":"Mol. Diversity"},{"key":"61309_CR23","doi-asserted-by":"publisher","first-page":"134238","DOI":"10.1016\/j.molstruc.2022.134238","volume":"1273","author":"P Padmaja","year":"2023","unstructured":"Padmaja, P. et al. Design, synthesis, in vitro \u03b1-glucosidase inhibitory, antioxidant activity and molecular docking studies of novel pyridine linked imidazo [1, 2-a] pyridine derivatives. J. Mol. Struct. 1273, 134238. https:\/\/doi.org\/10.1016\/j.molstruc.2022.134238 (2023).","journal-title":"J. Mol. Struct."},{"key":"61309_CR24","doi-asserted-by":"publisher","first-page":"42905","DOI":"10.1021\/acsomega.4c05619","volume":"9","author":"B Kaya","year":"2024","unstructured":"Kaya, B. et al. Synthesis, \u03b1-glucosidase, \u03b1-amylase, and aldol reductase inhibitory activity with molecular docking study of novel imidazo [1, 2-a] pyridine derivatives. ACS Omega 9, 42905\u201342914. https:\/\/doi.org\/10.1021\/acsomega.4c05619 (2024).","journal-title":"ACS Omega"},{"key":"61309_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59079-z","volume":"10","author":"F Peytam","year":"2020","unstructured":"Peytam, F. et al. An efficient and targeted synthetic approach towards new highly substituted 6-amino-pyrazolo [1, 5-a] pyrimidines with \u03b1-glucosidase inhibitory activity. Sci. Rep. 10, 2595. https:\/\/doi.org\/10.1038\/s41598-020-59079-z (2020).","journal-title":"Sci. Rep."},{"issue":"1","key":"61309_CR26","doi-asserted-by":"publisher","first-page":"11911","DOI":"10.1038\/s41598-021-91473-z","volume":"11","author":"F Peytam","year":"2021","unstructured":"Peytam, F. et al. Design, synthesis, molecular docking, and in vitro \u03b1-glucosidase inhibitory activities of novel 3-amino-2, 4-diarylbenzo [4, 5] imidazo [1, 2-a] pyrimidines against yeast and rat \u03b1-glucosidase. Sci. Rep. 1111911. https:\/\/doi.org\/10.1038\/s41598-021-91473-z (2021).","journal-title":"Sci. Rep."},{"key":"61309_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42549-5","volume":"13","author":"F Peytam","year":"2023","unstructured":"Peytam, F. et al. Imidazo [1, 2-c] quinazolines as a novel and potent scaffold of \u03b1-glucosidase inhibitors: Design, synthesis, biological evaluations, and in silico studies. Sci. Rep. 13, 15672. https:\/\/doi.org\/10.1038\/s41598-023-42549-5 (2023).","journal-title":"Sci. Rep."},{"key":"61309_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78878-2","volume":"14","author":"F Peytam","year":"2024","unstructured":"Peytam, F. et al. Design, synthesis, and evaluation of novel substituted imidazo [1, 2-c] quinazoline derivatives as potential \u03b1-glucosidase inhibitors with bioactivity and molecular docking insights. Sci. Rep. 14, 27507. https:\/\/doi.org\/10.1038\/s41598-024-78878-2 (2024).","journal-title":"Sci. Rep."},{"key":"61309_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01819-0","volume":"15","author":"F Peytam","year":"2025","unstructured":"Peytam, F. et al. Design, synthesis, and evaluation of triazolo [1, 5-a] pyridines as novel and potent \u03b1\u2011glucosidase inhibitors. Sci. Rep. 15, 17813. https:\/\/doi.org\/10.1038\/s41598-025-01819-0 (2025).","journal-title":"Sci. Rep."},{"key":"61309_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-23387-z","volume":"15","author":"F Peytam","year":"2025","unstructured":"Peytam, F. et al. Identification of novel triazolopyrimidines as potent \u03b1-glucosidase inhibitor through design, synthesis, biological evaluations, and computational analysis. Sci. Rep. 15, 39667. https:\/\/doi.org\/10.1038\/s41598-025-23387-z (2025).","journal-title":"Sci. Rep."},{"key":"61309_CR31","doi-asserted-by":"publisher","first-page":"51136","DOI":"10.1039\/d5ra07254a","volume":"15","author":"F Peytam","year":"2025","unstructured":"Peytam, F. et al. New coumarin\u2013chalcone\u2013triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validation. RSC Adv. 15, 51136\u201351161. https:\/\/doi.org\/10.1039\/d5ra07254a (2025).","journal-title":"RSC Adv."},{"key":"61309_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2026.109482","volume":"170","author":"F Peytam","year":"2026","unstructured":"Peytam, F. et al. Design, synthesis, and antidiabetic evaluation of triazolopyrimidine thioacetamides as potent and selective \u03b1-glucosidase inhibitors. Bioorg. Chem. 109482. https:\/\/doi.org\/10.1016\/j.bioorg.2026.109482 (2026).","journal-title":"Bioorg. Chem."},{"key":"61309_CR33","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3762\/bjoc.20.162","volume":"20","author":"C Martini","year":"2024","unstructured":"Martini, C., Mardjan, M. I. D. & Basso, A. The Groebke\u2013Blackburn\u2013Bienaym\u00e9 reaction in its maturity: Innovation and improvements since its 21st birthday (2019\u20132023). Beilstein J. Org. Chem. 20, 1839\u20131879. https:\/\/doi.org\/10.3762\/bjoc.20.162 (2024).","journal-title":"Beilstein J. Org. Chem."},{"key":"61309_CR34","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1021\/acsmedchemlett.2c00405","volume":"13","author":"Y Wu","year":"2022","unstructured":"Wu, Y., Liu, C. & Hu, L. Fragment-based dynamic combinatorial chemistry for identification of selective \u03b1-glucosidase inhibitors. ACS Med. Chem. Lett. 13, 1791\u20131796. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00405 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"61309_CR35","doi-asserted-by":"publisher","first-page":"13563","DOI":"10.1074\/jbc.M113.460436","volume":"288","author":"MK Barker","year":"2013","unstructured":"Barker, M. K. & Rose, D. R. Specificity of processing \u03b1-glucosidase I is guided by the substrate conformation: crystallographic and in silico studies. J. Biol. Chem. 288, 13563\u201313574. https:\/\/doi.org\/10.1074\/jbc.M113.460436 (2013).","journal-title":"J. Biol. Chem."},{"key":"61309_CR36","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0006-3495(01)76183-8","volume":"80","author":"JT Vivian","year":"2001","unstructured":"Vivian, J. T. & Callis, P. R. Mechanisms of tryptophan fluorescence shifts in proteins. Biophys. J. 80, 2093\u20132109. https:\/\/doi.org\/10.1016\/S0006-3495(01)76183-8 (2001).","journal-title":"Biophys. J."},{"key":"61309_CR37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ijbiomac.2018.03.143","volume":"114","author":"S Farhadian","year":"2018","unstructured":"Farhadian, S. et al. Insights into the molecular interaction between sucrose and \u03b1-chymotrypsin. Int. J. Biol. Macromol. 114, 950\u2013960. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.03.143 (2018).","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"61309_CR38","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41467-018-03597-y","volume":"9","author":"MW Van Der Kamp","year":"2018","unstructured":"Van Der Kamp, M. W. et al. Dynamical origins of heat capacity changes in enzyme-catalysed reactions. Nat. Commun. 91177. https:\/\/doi.org\/10.1038\/s41467-018-03597-y (2018).","journal-title":"Nat. Commun."},{"key":"61309_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus, M. & McCammon, J. A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9, 646\u2013652. https:\/\/doi.org\/10.1038\/nsb0902-646 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"61309_CR40","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s11030-023-10676-w","volume":"28","author":"F Peytam","year":"2024","unstructured":"Peytam, F. et al. Novel fluoroquinolones analogues bearing 4-(arylcarbamoyl) benzyl: Design, synthesis, and antibacterial evaluation. Mol. Divers. 28, 1577\u20131596. https:\/\/doi.org\/10.1007\/s11030-023-10676-w (2024).","journal-title":"Mol. Divers."},{"key":"61309_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejmech.2018.05.046","volume":"155","author":"M Adib","year":"2018","unstructured":"Adib, M. et al. New 6-amino-pyrido [2, 3-d] pyrimidine-2, 4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, \u03b1-glucosidase inhibition, molecular modeling and kinetic study. Eur. J. Med. Chem. 155, 353\u2013363. https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.046 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"61309_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1042\/bj0550170","volume":"55","author":"M Dixon","year":"1953","unstructured":"Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 55, 170. https:\/\/doi.org\/10.1042\/bj0550170 (1953).","journal-title":"Biochem. J."},{"key":"61309_CR43","doi-asserted-by":"publisher","first-page":"15835","DOI":"10.1016\/S0021-9258(18)71553-6","volume":"264","author":"MJ Todd","year":"1989","unstructured":"Todd, M. J. & Hausinger, R. Competitive inhibitors of Klebsiella aerogenes urease: mechanisms of interaction with the nickel active site. J. Biol. Chem. 264, 15835\u201315842. https:\/\/doi.org\/10.1016\/S0021-9258(18)71553-6 (1989).","journal-title":"J. Biol. Chem."},{"key":"61309_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106383","volume":"133","author":"Z Hasanvand","year":"2023","unstructured":"Hasanvand, Z. et al. Imidazo [1, 2-a] quinazolines as novel, potent EGFR-TK inhibitors: Design, synthesis, bioactivity evaluation, and in silico studies. Bioorg. Chem. 133, 106383. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106383 (2023).","journal-title":"Bioorg. Chem."},{"key":"61309_CR45","doi-asserted-by":"publisher","first-page":"W463","DOI":"10.1093\/nar\/gkaf361","volume":"53","author":"P Schake","year":"2025","unstructured":"Schake, P., Bolz, S. N., Linnemann, K. & Schroeder, M. PLIP 2025: introducing protein\u2013protein interactions to the protein\u2013ligand interaction profiler. Nucleic Acids Res. 53, W463\u2013W465. https:\/\/doi.org\/10.1093\/nar\/gkaf361 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61309-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61309-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:03:20Z","timestamp":1791907400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61309-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61309"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61309-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31944"}}